Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK

Diamantopoulos, Alex; Finckh, Axel; Huizinga, T; Sungher, D K; Sawyer, L; Neto, David; Dejonckheere, F

doi:10.1007/s40273-014-0165-7

Scientific article

Open access

English

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK

ContributorsDiamantopoulos, Alex; Finckh, Axel; Huizinga, T; Sungher, D K; Sawyer, L; Neto, David; Dejonckheere, F

Published inPharmacoEconomics, vol. 32, no. 8, p. 775-787

Publication date2014

Abstract

Since receiving a positive recommendation in England, Wales and Scotland, tocilizumab (TCZ) is one of the options available to clinicians for the treatment of rheumatoid arthritis (RA) patients in the UK.

Affiliation

Faculté de médecine / Section de médecine clinique / Département de médecine

Research group

Mécanisme de l'inflammation articulaire (44)

Citation (ISO format)

DIAMANTOPOULOS, Alex et al. Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK. In: PharmacoEconomics, 2014, vol. 32, n° 8, p. 775–787. doi: 10.1007/s40273-014-0165-7

Article (Published version)

Identifiers

PID : unige:45947
DOI : 10.1007/s40273-014-0165-7
PMID : 24854959

ISSN of the journal1179-2027

445views

432downloads

Creation01/27/2015 3:35:00 PM

First validation01/27/2015 3:35:00 PM

Update time03/14/2023 10:45:53 PM

Status update03/14/2023 10:45:53 PM

Last indexation01/16/2024 4:28:04 PM

Archive ouverte UNIGE

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK

Since receiving a positive recommendation in England, Wales and Scotland, tocilizumab (TCZ) is one of the options available to clinicians for the treatment of rheumatoid arthritis (RA) patients in the UK.

Technical informations